Glucagon-like peptide-1 analog: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Glucagon-like peptide-1 analog": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
| Line 21: | Line 21: | ||
{{Oral hypoglycemics and insulin analogs}} | {{Oral hypoglycemics and insulin analogs}} | ||
[[Category:Hormones]] | [[Category:Hormones]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 15:34, 9 August 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Glucagon-like peptide-1 analogs are a new class of drug for treatment of type 2 diabetes. [1] One of their advantages is that they have a lower risk of causing hypoglycemia.
Licenced:
- exenatide (2005)
Under investigation:
- albiglutide
- taspoglutide
References
- ↑ http://www.medscape.com/viewarticle/578304 "Glucagon-like Peptide-1 Analogs Other Than Exenatide"